<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157300</url>
  </required_header>
  <id_info>
    <org_study_id>P05-026</org_study_id>
    <nct_id>NCT00157300</nct_id>
  </id_info>
  <brief_title>PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation</brief_title>
  <official_title>PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo controlled, prospective trial investigating the effect of
      erythropoietin in renal transplantation.

      The investigators postulate that erythropoietin reduces the risk of delayed graft function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double blind, placebo controlled, prospective trial in patients, receiving a
      kidney transplantation. Patients will be randomized to receive either Epoetin Beta
      (Neorecormon; Roche) or placebo.

      The primary endpoint will be delayed graft function. The anticipated duration of this trial
      is 2 year and the target sample size is 60 patients per arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of delayed graft function and primary non function after kidney transplantation</measure>
    <time_frame>within12 weeks after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of dialysis treatment</measure>
    <time_frame>within 12 weeks after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of acute rejection episodes</measure>
    <time_frame>till one year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function at 3, 6 and 12 months</measure>
    <time_frame>3, 6 and 12 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient and graft survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Patients Receiving a Kidney From a Non-Heart-Beating Donor</condition>
  <arm_group>
    <arm_group_label>Epoetin beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin beta</intervention_name>
    <description>intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.</description>
    <arm_group_label>Epoetin beta</arm_group_label>
    <other_name>Neorecormon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  Receiving a kidney from a non-heart-beating donor category 3

        Exclusion Criteria:

          -  Donor related factors: a prolonged warm ischaemic time (&gt; 45 min); a cold ischaemic
             time of &gt; 24 hours; serum creatinin of &gt; 150 umol/l
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ton Rabelink, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Other transplantation centers</name>
      <address>
        <city>To Be Determined</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug;8(8):495-505.</citation>
    <PMID>12435860</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>July 30, 2010</last_update_submitted>
  <last_update_submitted_qc>July 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ton Rabelink, MD, PhD</name_title>
    <organization>Leiden University Medical Center</organization>
  </responsible_party>
  <keyword>erythropoietin</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>delayed graft function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

